317 related articles for article (PubMed ID: 33110170)
1. A pilot clinical study of the therapeutic antibody against canine PD-1 for advanced spontaneous cancers in dogs.
Igase M; Nemoto Y; Itamoto K; Tani K; Nakaichi M; Sakurai M; Sakai Y; Noguchi S; Kato M; Tsukui T; Mizuno T
Sci Rep; 2020 Oct; 10(1):18311. PubMed ID: 33110170
[TBL] [Abstract][Full Text] [Related]
2. A canine chimeric monoclonal antibody targeting PD-L1 and its clinical efficacy in canine oral malignant melanoma or undifferentiated sarcoma.
Maekawa N; Konnai S; Takagi S; Kagawa Y; Okagawa T; Nishimori A; Ikebuchi R; Izumi Y; Deguchi T; Nakajima C; Kato Y; Yamamoto K; Uemura H; Suzuki Y; Murata S; Ohashi K
Sci Rep; 2017 Aug; 7(1):8951. PubMed ID: 28827658
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical Analysis of PD-L1 Expression in Canine Malignant Cancers and PD-1 Expression on Lymphocytes in Canine Oral Melanoma.
Maekawa N; Konnai S; Okagawa T; Nishimori A; Ikebuchi R; Izumi Y; Takagi S; Kagawa Y; Nakajima C; Suzuki Y; Kato Y; Murata S; Ohashi K
PLoS One; 2016; 11(6):e0157176. PubMed ID: 27276060
[TBL] [Abstract][Full Text] [Related]
4. Cancer immunology and canine malignant melanoma: A comparative review.
Atherton MJ; Morris JS; McDermott MR; Lichty BD
Vet Immunol Immunopathol; 2016 Jan; 169():15-26. PubMed ID: 26827834
[TBL] [Abstract][Full Text] [Related]
5. Proof-of-concept study of the caninized anti-canine programmed death 1 antibody in dogs with advanced non-oral malignant melanoma solid tumors.
Igase M; Inanaga S; Nishibori S; Itamoto K; Sunahara H; Nemoto Y; Tani K; Horikirizono H; Nakaichi M; Baba K; Kambayashi S; Okuda M; Sakai Y; Sakurai M; Kato M; Tsukui T; Mizuno T
J Vet Sci; 2024 Jan; 25(1):e15. PubMed ID: 38311328
[TBL] [Abstract][Full Text] [Related]
6. Efficient adenovector CD40 ligand immunotherapy of canine malignant melanoma.
von Euler H; Sadeghi A; Carlsson B; Rivera P; Loskog A; Segall T; Korsgren O; Tötterman TH
J Immunother; 2008 May; 31(4):377-84. PubMed ID: 18391758
[TBL] [Abstract][Full Text] [Related]
7. Development and characterization of mouse anti-canine PD-L1 monoclonal antibodies and their expression in canine tumors by immunohistochemistry
Sirivisoot S; Boonkrai C; Wongtangprasert T; Phakham T; Muanwein P; Pisitkun T; Sawangmake C; Radtanakatikanon A; Rungsipipat A
Vet Q; 2023 Dec; 43(1):1-9. PubMed ID: 37477617
[TBL] [Abstract][Full Text] [Related]
8. PD-L1 immunohistochemistry for canine cancers and clinical benefit of anti-PD-L1 antibody in dogs with pulmonary metastatic oral malignant melanoma.
Maekawa N; Konnai S; Nishimura M; Kagawa Y; Takagi S; Hosoya K; Ohta H; Kim S; Okagawa T; Izumi Y; Deguchi T; Kato Y; Yamamoto S; Yamamoto K; Toda M; Nakajima C; Suzuki Y; Murata S; Ohashi K
NPJ Precis Oncol; 2021 Feb; 5(1):10. PubMed ID: 33580183
[TBL] [Abstract][Full Text] [Related]
9. Bone marrow-derived dendritic cell vaccination of dogs with naturally occurring melanoma by using human gp100 antigen.
Gyorffy S; Rodriguez-Lecompte JC; Woods JP; Foley R; Kruth S; Liaw PC; Gauldie J
J Vet Intern Med; 2005; 19(1):56-63. PubMed ID: 15715049
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant therapy for melanoma in dogs: results of randomized clinical trials using surgery, liposome-encapsulated muramyl tripeptide, and granulocyte macrophage colony-stimulating factor.
MacEwen EG; Kurzman ID; Vail DM; Dubielzig RR; Everlith K; Madewell BR; Rodriguez CO; Phillips B; Zwahlen CH; Obradovich J; Rosenthal RC; Fox LE; Rosenberg M; Henry C; Fidel J
Clin Cancer Res; 1999 Dec; 5(12):4249-58. PubMed ID: 10632367
[TBL] [Abstract][Full Text] [Related]
11. Development and pharmacokinetic assessment of a fully canine anti-PD-1 monoclonal antibody for comparative translational research in dogs with spontaneous tumors.
Yoshimoto S; Chester N; Xiong A; Radaelli E; Wang H; Brillantes M; Gulendran G; Glassman P; Siegel DL; Mason NJ
MAbs; 2023; 15(1):2287250. PubMed ID: 38047502
[TBL] [Abstract][Full Text] [Related]
12. Potential to involve multiple effector cells with human recombinant interleukin-2 and antiganglioside monoclonal antibodies in a canine malignant melanoma immunotherapy model.
Helfand SC; Soergel SA; Donner RL; Gan J; Hank JA; Lindstrom MJ; Sondel PM
J Immunother Emphasis Tumor Immunol; 1994 Oct; 16(3):188-97. PubMed ID: 7834118
[TBL] [Abstract][Full Text] [Related]
13. Cancer Immunotherapies.
Bergman PJ
Vet Clin North Am Small Anim Pract; 2019 Sep; 49(5):881-902. PubMed ID: 31186125
[TBL] [Abstract][Full Text] [Related]
14. Programmed Cell Death Ligand 1 Expression in Canine Cancer.
Shosu K; Sakurai M; Inoue K; Nakagawa T; Sakai H; Morimoto M; Okuda M; Noguchi S; Mizuno T
In Vivo; 2016; 30(3):195-204. PubMed ID: 27107075
[TBL] [Abstract][Full Text] [Related]
15. Comparative characterization of two monoclonal antibodies targeting canine PD-1.
Kocikowski M; Dziubek K; Węgrzyn K; Hrabal V; Zavadil-Kokas F; Vojtesek B; Alfaro JA; Hupp T; Parys M
Front Immunol; 2024; 15():1382576. PubMed ID: 38779661
[TBL] [Abstract][Full Text] [Related]
16. Development and characterization of monoclonal antibodies against canine PD-1 and PD-L1.
Nemoto Y; Shosu K; Okuda M; Noguchi S; Mizuno T
Vet Immunol Immunopathol; 2018 Apr; 198():19-25. PubMed ID: 29571514
[TBL] [Abstract][Full Text] [Related]
17. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
18. [Combined use of irradiation and DNA tumor vaccine to treat canine oral malignant melanoma: a pilot study].
Herzog A; Buchholz J; Ruess-Melzer K; Lang J; Kaser-Hotz B
Schweiz Arch Tierheilkd; 2013 Feb; 155(2):135-42. PubMed ID: 23385072
[TBL] [Abstract][Full Text] [Related]
19. Bladder cancer, a unique model to understand cancer immunity and develop immunotherapy approaches.
Song D; Powles T; Shi L; Zhang L; Ingersoll MA; Lu YJ
J Pathol; 2019 Oct; 249(2):151-165. PubMed ID: 31102277
[TBL] [Abstract][Full Text] [Related]
20. Bispecific Antibody Approach for Improved Melanoma-Selective PD-L1 Immune Checkpoint Blockade.
Koopmans I; Hendriks MAJM; van Ginkel RJ; Samplonius DF; Bremer E; Helfrich W
J Invest Dermatol; 2019 Nov; 139(11):2343-2351.e3. PubMed ID: 31128201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
